A Case of Vaccine-Preventable Back Pain by Hutfles, Gerald & James, Tricia
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Providence Portland Medical Center Internal 
Medicine 2021 
Providence Portland Medical Center Internal 
Medicine 
5-2021 
A Case of Vaccine-Preventable Back Pain 
Gerald Hutfles 
Tricia James 
Follow this and additional works at: https://digitalcommons.psjhealth.org/oaa_ppmc_21 
 Part of the Internal Medicine Commons 
A Case of Vaccine-Preventable Back Pain
Gerald Hutfles, DO, Tricia James, MD
The Case
HPV – That Bad, Insidious Bug
Anal Cancer – Decreasing the Risk
Learning Points
References
Flex Sigmoidoscopy – Month 9
What is it?
• Human Papillomavirus (HPV) is a double-stranded DNA virus of the 
Papillomaviridae family.  Its lifecycle is tied to epithelial tissue.
Why do we care?
• HPV is associated with warts (including condyloma acuminatum) and cancer
• Approximately 45,000 HPV-associated cancers occur in the US each year
• 7,083 - anal cancer
• 12,143 - cervical cancer
• 19,975 - oropharyngeal cancer
What About Anal Cancer?
• Affects ~1.6/100,000 women, and 1.0/100,000 men in the United States
• Rates increase in men who have sex with men (MSM) at rates of 35/100,000 
of those who are HIV-negative and 70-100/100,000 in those who are HIV-
positive
• 5-year survival is 82% if T2N0, 42% survival if T4N+.
Vaccination
• One studied showed an incidence rate ratio for HGSIL in females vaccinated 
for HPV compared to an unvaccinated population was 0.516
• Likely translates to other HPV-related disease, but further studies are 
needed
Screening
• One retrospective study - 39% lower mortality risk in anal SCC in areas with 
higher anal dysplasia screening rates1
• No consensus on who should be screened for anal cancer and what the 
primary modality should be.
• Recommended in HIV-infected MSM
• Consider screening in:
• HIV+ men & women 
• MSM
• HIV-negative women over the age of 45 with cervical HPV 16
• Pts with history of anal warts
• Women with a history of high-grade cervical, vulvar or vaginal 
dysplasia or cancer
• Immunosuppressed patients 
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55-year-old male with minimal medical history who presented 
multiple times over 9 months with progressive and severe gluteal 
& back pain, ultimately found to be from anal cancer.
1. Anal cancer may present in an atypical fashion.  It is important to 
consider it in the differential of buttock/back pain, particularly for patients 
with risk factors
2. HPV is associated with cancers that are preventable through cancer 
screening & vaccination.
3. No standardized methodology or guidelines exist for evaluation of anal 
cancer, but studies are underway.
4. Certain subpopulations with risk factors that predispose them to an 
increased risk of anal cancer should be screened for this disease.
Anal Cancer Screening Modalities
PCP visit for bilateral 
gluteal pain, was treated 
symptomatically.
6 mo:  Pain is now in low back and 
radicular to his right hip. Referred to 
ortho.  MRI Lumbar spine & right hip 
WNL. 
7 mo:  Progressive pain.  
Referred to pain management, 
started on Pregabalin, epidural 
steroid injection given with 
minimal relief.
9 mo:  Admitted for severe pain.  
CT abd/pelvis with rectal wall 
thickening, f/u flex sig & biopsy with 
poorly-differentiated P16+ SCC of 
the rectum.  PET with diffuse mets
Medical History: major depressive 
disorder, anal warts, hypogonadism
• Up to date on all health maintenance 
Social History:
• Lives with same-sex partner of 15 years, 
no recent sexual activity.
• Substance Use:  Former distant smoker, 
no recreational drug use, 14 drinks per 
week
Initial Physical Exam:
• Neuro:  No neurologic deficits, normal 
sensation of perineum & upper/lower 
extremities. Normal DTRs
• Musculoskeletal:  5/5 strength in all 
extremities.  Tenderness to palpation of 
ischial tuberosities and coccyx.
Time Course 
(A)  Rectum (B)  Sigmoid Colon
Cancer Rates per CDC Data
https://seer.cancer.gov/statfacts/html/anus.html https://seer.cancer.gov/statfacts/html/cervix.html







Benefits Simple, performed 
by provider or 
patient, cost-
efficient
Gold standard, allows 




provider or patient; 
overall good 
sensitivity (up to 
93%)
Detriments Not well-validated, 
not studied formally





8 mo: Multiple ED visits for 
pain. Started on opiates. 
Seen by neurosurgery.  CT 
Lumbar spine & bone scan 
WNL.  Developed intermittent 
hematochezia, referred to GI.
9.5 months:  Progressive 
pain and decline. Had 
multiple small-vessel strokes.  
Transitioned to comfort care 
and died.
